MENU

Why these 4 ASX shares are dropping lower today

The S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) is on course to post a solid gain on Thursday. In afternoon trade the benchmark index has followed the lead of Wall Street and is up over 0.4% to 5,750.2 points.

Four shares that have failed to follow the market higher today are listed below. Here’s why they are dropping lower:

The Bellamy’s Australia Ltd (ASX: BAL) share price has fallen 4.5% to $7.30 following the release of an investor day presentation. Although the presentation was very positive and painted a bright future for the infant formula company, it also revealed that it is still waiting for its SAMR application to be approved. This is required to sell its Chinese label products on the China mainland and its delay has led to a significant slowdown in sales growth.

The Bubs Australia Ltd (ASX: BUB) share price has dropped 6% to 46.5 cents. The goats milk infant formula company’s shares rose strongly on Wednesday after it provided a positive sales update at its annual general meeting. I suspect that today’s decline could be attributable to profit taking from some traders.

The Gentrack Group Ltd (ASX: GTK) share price has tumbled 6% to $5.75 after the billing software company released its preliminary final report. For the 12 months ending September 30 Gentrack delivered a 39% lift in revenue to NZ$104.5 million and a 17.3% increase in net profit to NZ$13.9 million. However, management warned that there is significant investment uncertainty amongst its utility customers in key markets which could impact its FY 2019 performance.

The Mayne Pharma Group Ltd (ASX: MYX) share price has fallen 7% to 96.5 cents on the day of its annual general meeting. Although the pharmaceutical company reported strong growth in revenue and gross profit for the first four months of FY 2019, the lack of half or full year guidance appears to have spooked investors and sent some to the exits today.

5 Companies we like better than Mayne Pharma

When ace stock picker Scott Phillips has a buy recommendation, history suggests it can pay to listen.

Scott recently revealed what he believes are the five best ASX stocks for investors to buy right now… and Mayne Pharma wasn’t one of them! That’s right — he thinks these 5 stocks are even better buys.

See the 5 stocks

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended GENTRACK FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.